Acta Med. 2022, 65: 83-88
https://doi.org/10.14712/18059694.2022.23
Risk Factors for Candidemia in Intensive Care Unit: A Matched Case Control Study from North-Western India
References
1. S, Das S, Chawan NS, Hazra A. Nosocomial infections in the intensive care unit: incidence, risk factors, outcome and associated pathogens in a public tertiary teaching hospital of Eastern India. Indian J Crit Care Med 2015; 19: 14–20.
2. N. Epidemiology and risk factors for invasive candidiasis. Ther Clin Risk Manag 2014 Feb 13; 10: 95–105.
<https://doi.org/10.2147/TCRM.S40160>
<PubMed>
3. Rajni E, Chaudhary P, Garg VK, Sharma R, Malik M. A complete clinico-epidemiological and microbiological profile of candidemia cases in a tertiary-care hospital in Western India. Antimicrobial Stewardship & Healthcare Epidemiology. Cambridge University Press 2022; 2(1): e37.
4. A, Sood P, Rudramurthy SM, et al. Incidence, characteristics and outcome of ICU-acquired candidemia in India. Intensive Care Med 2015; 41(2): 285–95.
<https://doi.org/10.1007/s00134-014-3603-2>
5. S, Kumar S, Rajpal K, et al. Candidemia Among ICU Patients: Species Characterisation, Resistance Pattern and Association with Candida Score: A Prospective Study. Cureus 2022; 14(4): e24612.
6. J, Damonti L, Bignon A, et al. Risk factors for candidemia: a prospective matched case-control study. Crit Care 2020; 24(1): 109.
<https://doi.org/10.1186/s13054-020-2766-1>
<PubMed>
7. E, Singh A, Tarai B, et al. A High Frequency of Candida auris Blood Stream Infections in Coronavirus Disease 2019 Patients Admitted to Intensive Care Units, Northwestern India: A Case Control Study. Open Forum Infect Dis 2021; 8(12): ofab452.
<https://doi.org/10.1093/ofid/ofab452>
<PubMed>
8. F, Magnasco L, Sepulcri C, et al. Candida auris Candidemia in Critically Ill, Colonized Patients: Cumulative Incidence and Risk Factors. Infect Dis Ther 2022; 11(3): 1149–60.
<https://doi.org/10.1007/s40121-022-00625-9>
<PubMed>
9. Z, Wang Q, Zhu F, An Y. Epidemiology, species distribution, antifungal susceptibility and mortality risk factors of candidemia among critically ill patients: a retrospective study from 2011 to 2017 in a teaching hospital in China. Antimicrob Resist Infect Control 2019; 8: 89.
<https://doi.org/10.1186/s13756-019-0534-2>
<PubMed>
10. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Anti–Fungal Susceptibility Testing of Yeasts. CLSI Document M27. 4th ed. Wayne, PA: Clinical and Laboratory Standards Institute 2017.
11. C, Meletiadis J, Charitidou E, et al. Epidemiology of Candidemia and Fluconazole Resistance in an ICU before and during the COVID-19 Pandemic Era. Antibiotics 2022; 11: 771.
<https://doi.org/10.3390/antibiotics11060771>
<PubMed>
12. AM, Peman J, Bernhardt H, et al.: Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004; 23: 317–22.
<https://doi.org/10.1007/s10096-004-1103-y>
13. S, Kindo AJ, Kalyani J. Candidemia in intensive care unit patients: a one year study from a tertiary care center in South India. J Postgrad Med 2013; 59(3): 190–5.
<https://doi.org/10.4103/0022-3859.118036>
14. H, Singh S, Rudramurthy SM, et al. Candidaemia in a tertiary care centre of developing country: Monitoring possible change in spectrum of agents and antifungal susceptibility. Indian J Med Microbiol 2020; 38(1): 110–6.
<https://doi.org/10.4103/ijmm.IJMM_20_112>
15. A, Sharma A. The lurking scourge of multidrug resistant Candida auris in times of COVID-19 pandemic. J Glob Antimicrob Resist 2020; 22: 175–6.
<https://doi.org/10.1016/j.jgar.2020.06.003>
<PubMed>
16. P, Epelbaum O. Epidemiology and Mycology of Candidaemia in non-oncological medical intensive care unit patients in a tertiary center in the United States: Overall analysis and comparison between non-COVID-19 and COVID-19 cases. Mycoses 2021; 64(6): 634–40.
<https://doi.org/10.1111/myc.13258>
<PubMed>
17. D, Lyngdoh WV, Bora I, Prasad A, Debnath K, Elantamilan D. Prevalence of non-albicans candidemia in a tertiary-care hospital in Northeast India. Int J Med Sci Public Health 2017; 6: 1620–5.
18. A, Sagar V. Epidemiology of candida bloodstream infections in a tertiary care institute in India. Indian J Med Microbiol 2009; 27(2): 171–2.
<https://doi.org/10.4103/0255-0857.49440>
19. DO, Schlattmann P, Pletz M, Kurzai O, Bloos F. Risk Factors for Invasive Candida Infection in Critically Ill Patients: A Systematic Review and Meta-analysis. Chest 2022; 161(2): 345–55.
<https://doi.org/10.1016/j.chest.2021.08.081>
<PubMed>
20. D, Xia R, Zhang Q, Bai C, Li Z, Zhang P. Evaluation of candidemia in epidemiology and risk factors among cancer patients in a cancer center of China: an 8-year case-control study. BMC Infect Dis 2017; 17(1): 536.
<https://doi.org/10.1186/s12879-017-2636-x>
<PubMed>
21. M, Barreiros G, Guimaraes LF, Deriquehem VAS, Castineiras AC, Nouer SA. Increased incidence of candidemia in a tertiary care hospital with the COVID-19 pandemic. Mycoses 2021; 64: 152–6.
<https://doi.org/10.1111/myc.13225>
<PubMed>
22. CVW, Cassol R, Pasqualotto AC. Is the frequency of candidemia increasing in COVID-19 patients receiving corticosteroids? J Fungi 2020; 6: 286.
<https://doi.org/10.3390/jof6040286>
<PubMed>
23. FV, Bavaro DF, Di Gennaro F, et al. Impact of SARS-CoV-2 Epidemic on Antimicrobial Resistance: A Literature Review. Viruses 2021; 13: 2110.
<https://doi.org/10.3390/v13112110>
<PubMed>
24. Y, Zhang X, Yue T, et al. Combination of C-Reactive Protein and Procalcitonin in Distinguishing Fungal from Bacterial Infections Early in Immunocompromised Children. Antibiotics 2022; 11(6): 730.
<https://doi.org/10.3390/antibiotics11060730>
<PubMed>
25. P. Providencial Progression: Time tobe Intolerant. Indian J Crit Care Med 2022; 26(4): 409–10.
<https://doi.org/10.5005/jp-journals-10071-24192>
<PubMed>
